V-Wave launches pivotal interatrial shunt trial

V-Wave said today it launched a new trial of its minimally invasive interartrial shunt designed to treat patients with symptomatic heart failure. The new Relieve-HF trial aims to enroll 500 patients in a pivotal study of the device, which is designed for patients with NHYA Class III and ambulatory Class IV symptomatic heart failure, the Israel-based company said. “The interatrial shunt provides a novel therapeutic approach for patients with chronic HF. The shunt is implanted through a catheter inserted in a vein in the leg. Prior clinical experience demonstrated device and implantation procedure safety, and statistically significant improvements in symptoms, quality of life measurements, and exercise capacity were observed compared to a matched population receiving optimal care. We are fortunate to have our study designed by the world’s leading HF clinical trialists: Drs. William Abraham from the Ohio State University, Gregg Stone, from Columbia University, JoAnn Lindenfeldof Vanderbilt University, Stefan D. Anker from Charité Berlin, Germany, and Josep Rodés-Cabau, MD, Laval University, Quebec.  These extraordinary physicians have planned and executed some of the most influential and successful HF and structural heart disease device trials,” CEO Dr. Neal Eigler said in a press release. V-Wave said that it has enrolled two patients in the study so far, and that both were...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials V-Wave Source Type: news

Related Links:

This study defines a new clinically relevant concept of T-cell senescence-mediated inflammatory responses in the pathophysiology of abnormal glucose homeostasis. We also found that T-cell senescence is associated with systemic inflammation and alters hepatic glucose homeostasis. The rational modulation of T-cell senescence would be a promising avenue for the treatment or prevention of diabetes. Intron Retention via Alternative Splicing as a Signature of Aging https://www.fightaging.org/archives/2019/03/intron-retention-via-alternative-splicing-as-a-signature-of-aging/ In recent years researchers have inv...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Failing Fontan circulation patients are one of the fastest growing cohorts with heart failure presenting to congenital programs. We sought to describe their outcomes by combining two databases.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 261 Source Type: research
This study tested the hypothesis that HF hospitalizations and resource utilization among ACHD patients in the United States are significantly increasing.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 484 Source Type: research
Cardiac resynchronization therapy (CRT) has been shown to shorten QRS duration (QRSd) and improve ejection fraction (EF) in adults with congenital heart disease (ACHD) and children with heart failure with reduced ejection fraction (HFrEF). It is not known whether CRT confers a survival benefit. We sought to determine whether CRT is associated with longer transplant-free survival after adjusting for patient factors.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 478 Source Type: research
Heart failure is a significant cause of morbidity and mortality in congenital heart disease patients especially for the subset whose right ventricle functions as the systemic ventricle. The physiological and molecular differences in the right ventricle (RV) and left ventricle (LV) lead to different abilities to adapt to adverse conditions and respond to pharmacological therapeutics. Currently data describing the molecular changes that occur in the systemic RV are lacking. Available animal models create an RV with volume and/or pressure overload however the LV remains at high pressure.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 600 Source Type: research
Two separate studies by Morris et al. in 1964 and then He at al in 2017 were able to show a direct relationship between P wave analysis and valvular heart disease and ischemic stroke, respectively. We hope to continue this progress by establishing a relationship between P wave morphology, duration, PR interval, and P wave terminal force with the severity of Heart Failure with Preserved Ejection Fraction in our patient population.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 956 Source Type: research
Due to impressive improvements in surgical treatment, patients with complex CHD have better survival and may develop end-stage heart failure. The number of patients with CHD that need heart (HT) or heart-lung transplantation (HLT) has been increasing in the last decades. The purpose of our study is (1) to review our experience in these patients and (2) to describe perioperative course and outcomes of ACHD patients who required HT or HLT in our institution in the last 4 years.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 1004 Source Type: research
In this study we aimed to characterize the extend of palliative care service's participation in the care of patients requiring VAD placement at our institution.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 1210 Source Type: research
Abstract Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH). The prognosis of PVOD patients remains poor, since no effective medical therapy is yet available. Imatinib is a tyrosine kinase inhibitor specific for platelet-derived growth factor receptor and is expected as a treatment option for pulmonary arterial hypertension (PAH). Recently, it has been reported that imatinib improved functional capacity of a patient with PVOD. We here report a patient with suspected PVOD who has been successfully treated with imatinib and is alive for 6 years after diagnosis. A 57-year-old woman ...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
The number of heart and lung transplantations has risen over the years, and they remain the mainstay of treatment for end-stage heart failure and end-stage lung diseases. From the assessment of the donor's heart to intraoperative management during separation from cardiopulmonary bypass (CPB) to the postoperative follow-up of heart transplant patients, echocardiography plays a vital role throughout this process. Patients with chronic lung diseases also may have cardiovascular compromise secondary to pulmonary hypertension, pre-existing coronary artery disease, or valvular heart disease.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Review Article Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Germany Health | Heart | Heart Disease | Heart Failure | Heart Transplant | Hospitals | Israel Health | Lung Transplant | Middle East Health | Sports Medicine | Statistics | Study | Transplant Surgery | Transplants